Bronchial asthma is a common chronic respiratory disease,which is characterized by chronic airway inflamma-tion and airway hyperresponsiveness.The clinical manifestations are often recurrent wheezing,shortness of breath,chest tightness,cough,and other symptoms.Patients with moderate to severe asthma have recurrent symptoms,which often lead to decreased lung function if they cannot be effectively controlled.In recent years,as a new biological preparation for treating severe asthma,biologically targeted drugs have provided more treatment options for asthma patients.At present,the main clinical applications include anti IgE monoclonal antibodies,anti IL-4 receptor monoclonal antibodies,and anti IL-5 receptor monoclonal antibodies.Dupilumab,as a targeted biological drug,has a significant effect in the treatment of moderate to severe bronchial asthma.It can bind to IL-4Rα with high affinity and block the signal transduction of IL-4 and IL-13,thereby inhibiting type 2 airway inflammation,improving pulmonary symptoms,and controlling asthma at-tacks.Asthma patients treated with dupilumab not only improve their quality of life,but also reduce the dosage of glu-cocorticoids and alleviate a series of side effects caused by long-term use of glucocorticoids.Moreover,the safety of dupi-lumab in the treatment of asthma is good,with few serious adverse reactions.The common adverse reactions are mild and short-lived,and often can be relieved by themselves.Dupilumab provides a new strategy for the treatment of patients with asthma,and is the recommended drug for severe asthma in domestic and foreign guidelines.However,at present,the do-mestic market was launched relatively late,there are few research reports,the clinical research cycle is short,the sample size data is limited,and long-term research and observation are still needed.This article will review the clinical treatment progress of dupilumab in the treatment of moderate to severe bronchial asthma,providing a basis for further research.
维普
万方数据
